Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

29 Nov 2021

Abstract excerpt

INTRODUCTION: The chemoresistance mechanism of diffuse large B-cell lymphoma (DLBCL) is still poorly understood, and patient prognosis remains unsatisfactory. This study aimed to investigate drug resistance mechanisms in non-germinal center B-cell-like (non-GCB) DLBCL. METHODS: Doxorubicin (DOX)-resistant OCI-Ly3 cells were generated through long-term incubation of cells in a medium with gradually increasing DOX...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to CNS Lymphoma Diagnosis and Treatment
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34844236
DOI: 10.1159/000520070

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaPMID 34844236Read ↗

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).Semantic proximity Read ↗

Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphomaSemantic proximity Read ↗

Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.Semantic proximity Read ↗

Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance.Semantic proximity Read ↗

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.Semantic proximity Read ↗

MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients.Semantic proximity Read ↗

BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T‐cell lymphoblastic lymphomaSemantic proximity Read ↗

EFNB1 level affects drug response in DLBCL cell linesSemantic proximity Read ↗

Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map databaseSemantic proximity Read ↗

Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.Semantic proximity Read ↗

MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphomaSemantic proximity Read ↗

High BECN1 Expression Negatively Correlates with BCL2 Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of AutophagySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.